Apellis Pharmaceuticals Inc
(NAS:APLS)
$
40.07
-0.26 (-0.64%)
Market Cap: 4.86 Bil
Enterprise Value: 4.65 Bil
PE Ratio: 0
PB Ratio: 18.22
GF Score: 38/100 - Q1 2024 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024$43.9 (-10.06%)Earnings
- Q4 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2024$69.35 (-3.32%)Earnings
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare C-Suite Unscripted Conference TranscriptJan 04, 2024
- Apellis Pharmaceuticals Inc to Discuss the CHMP Trend Vote TranscriptDec 14, 2023
- Apellis Pharmaceuticals Inc at Evercore ISI HealthCONx Conference TranscriptNov 28, 2023
- Q3 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 01, 2023$49.9 (+2.55%)Earnings
- Apellis Pharmaceuticals Inc at Robert W Baird Global Healthcare Conference TranscriptSep 12, 2023
- Apellis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Apellis Pharmaceuticals Inc at Wells Fargo Healthcare Conference TranscriptSep 08, 2023
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptJul 31, 2023$25.75 (-19.58%)Earnings
- Apellis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2023$84.37 (-0.76%)Earnings
- Apellis Pharmaceuticals Inc SYFOVRE FDA Approval Call TranscriptFeb 17, 2023
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Apellis Pharmaceuticals Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Q3 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2022$47.62 (-5.55%)Earnings
- Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptSep 16, 2022
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference TranscriptSep 07, 2022
- Apellis Pharmaceuticals Inc Corporate Call TranscriptAug 24, 2022
- Q2 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2022$62.33 (-1.58%)Earnings
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Apellis Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Apellis Pharmaceuticals Inc at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 Apellis Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2022$45.95 (+3.00%)Earnings
- Apellis Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Apellis Pharmaceuticals Inc DERBY and OAKS 18 Month Data Conference Call TranscriptMar 16, 2022
- Apellis Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) TranscriptMar 09, 2022
- Q4 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 28, 2022$42.53Earnings
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Apellis Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 10, 2021
- Q3 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptNov 08, 2021$33.69 (-1.35%)Earnings
- Apellis Pharmaceuticals Inc Announces results from Phase 3Â DERBY and OAKS TranscriptSep 09, 2021
- Q2 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptAug 09, 2021$62 (-2.18%)Earnings
- Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually TranscriptJun 30, 2021
- Apellis Pharmaceuticals Inc at Bank of America NAPA Healthcare Conference TranscriptJun 16, 2021
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Apellis Pharmaceuticals Inc EMPAVELI FDA Approval Call TranscriptMay 17, 2021
- Q1 2021 Apellis Pharmaceuticals Inc Earnings Call TranscriptApr 28, 2021$45.3 (-0.33%)Earnings
- Q4 2020 Apellis Pharmaceuticals Inc Earnings Call TranscriptFeb 25, 2021$45.05 (-2.49%)Earnings
- Apellis Pharmaceuticals Inc Virtual Investorm Meeting - Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) TranscriptJan 28, 2021
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Apellis Pharmaceuticals Inc Sobi Strategic Collaboration Conference Call TranscriptOct 27, 2020
- Apellis Pharmaceuticals Inc The Evolution of Complement Targeted Therapies Panel at Stifel Immunology & Inflammation Summit (Virtual) TranscriptOct 01, 2020
- Apellis Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) - Fireside Chat TranscriptSep 10, 2020
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- Apellis Pharmaceuticals Inc to Discuss Phase 3 PEGASUS Study Results - Conference Call TranscriptJun 12, 2020
- Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Apellis Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Apellis Pharmaceuticals, Inc. - Special Call TranscriptJan 07, 2020
- Apellis Pharmaceuticals Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Editas Medicine Inc, Apellis Pharmaceuticals Inc and Rigel Pharmaceuticals Inc at Citi Biotech Conference TranscriptSep 05, 2019
Apellis Pharmaceuticals Inc The Evolution of Complement Targeted Therapies Panel at Stifel Immunology & Inflammation Summit (Virtual) Transcript
Oct 01, 2020 / 01:00PM GMT
Release Date Price:
$31.77
(+5.30%)
Derek Christian Archila
Stifel, Nicolaus & Company, Incorporated, Research Division - Director & Senior Analyst
Hey, good morning, everyone, and thanks for joining us for the first Annual Immunology and Inflammation Summit here at Stifel. I hope you're all doing well and staying safe.
So today, we're going to be assessing some of the hot topics in this therapeutic area. And we're kicking this event off today with our panel on complement-targeted therapies.
So with us today for the first panel this morning, we have Dr. Cedric Francois, the CEO of Apellis Pharmaceuticals. And then also, we have Grant Blouse, the Senior Vice President of Translational Research at Catalyst Bio. So gentlemen, thank you so much for joining us this morning.
Grant Blouse
Catalyst Biosciences, Inc. - SVP of Translational Research
Thank you.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
[It's great.]
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)